Preventive Mastectomies Triple for U.S. Women Over Past Decade

Share this content:
Preventive Mastectomies Triple for U.S. Women Over Past Decade
Preventive Mastectomies Triple for U.S. Women Over Past Decade

MONDAY, March 14, 2016 (HealthDay News) -- The number of U.S. breast cancer patients choosing to have a healthy breast removed has tripled in the past decade, even though this aggressive measure offers no significant survival benefits for women with cancer in one breast, according to a study published online March 8 in the Annals of Surgery.

Mehra Golshan, M.D., chair of surgical oncology at Brigham and Women's Hospital in Boston, and colleagues analyzed data from 496,488 women who were diagnosed with stage I, II, or III cancer in one breast and followed for more than eight years. Of those patients, 59.6 percent overall had breast-conserving surgery, one-third (33.4 percent) had the diseased breast removed, and 7.0 percent had their healthy breast removed as well.

Rates of contralateral prophylactic mastectomy increased from 3.9 percent in 2002 to 12.7 percent in 2012. But women who had their unaffected breast removed did not have significantly higher survival rates than those who had breast-conserving surgery, the researchers found. White patients were the most likely to have the healthy breast removed.

"Understanding why women choose to undergo contralateral prophylactic mastectomy may create an opportunity for health care providers to optimally counsel women about surgical options, address anxieties, discuss individual preferences, and ensure peace of mind related to a patient's surgical choice," Golshan said in a hospital news release.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »